ASCO 2024 preview – Astra’s plenary double
Abstract titles reveal some of ASCO’s key datasets.
Volastra vies for the next big synthetic lethality target
The group reckons big pharma is eyeing KIF18A inhibition, but for now there are just a handful of players.
CCR8 expectations
Blockade of CCR8 has quietly emerged as a hot oncology target, especially for anti-PD-(L)1 MAb combinations.
Merck makes haste to catch up in KRAS
The company is setting up another battle with Bristol Myers Squibb, while Amgen has different plans.
ProfoundBio takeout shines a light on Sutro
Genmab’s remarkably bold acquisition raises more questions about Sutro, a key FRα rival of ProfoundBio.
FDA green and red lights: Q1 2024
A roundup of the first quarter's key oncology drug approvals and rejections.
